MT4-(MMP17) and MT6-MMP (MMP25), a unique set of membrane-anchored matrix metalloproteinases: Properties and expression in cancer

Cancer and Metastasis Reviews

Volumn 27, Issue 2, 2008, Pages 289-302

  Sohail, Anjum ^a   Sun, Qing ^a   Zhao, Huiren ^a   Bernardo, M Margarida ^a   Cho, Jin Ah ^a   Fridman, Rafael ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Extracellular matrix; Glycosyl phosphatidyl inositol; Lipid raft; Matrix metalloproteinases; Membrane anchor; Plasma membrane; Protease inhibitors; Proteolysis

Indexed keywords

GELATINASE A; GELATINASE B; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 25; MESSENGER RNA;

BIOSYNTHESIS; BREAST CARCINOMA; CELL MEMBRANE; CELL SURFACE; CELLULAR DISTRIBUTION; ENDOCYTOSIS; HUMAN; LIPID RAFT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; CELL MEMBRANE; HUMANS; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; NEOPLASMS;

EID: 43049084341     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-008-9129-8     Document Type: Review

References (102)

1. McCawley, L. J., & Matrisian, L. M. (2000). Matrix metalloproteinases: Multifunctional contributors to tumor progression. Molecular Medicine Today, 6, 149-156.
2. Stamenkovic, I. (2000). Matrix metalloproteinases in tumor invasion and metastasis. Seminars in Cancer Biology, 10, 415-433.
3. Itoh, Y., & Nagase, H. (2002). Matrix metalloproteinases in cancer. Essays in Biochemistry, 38, 21-36.
4. Lafleur, M. A., Handsley, M. M., & Edwards, D. R. (2003). Metalloproteinases and their inhibitors in angiogenesis. Expert Reviews in Molecular Medicine, 5, 1-39.
5. Deryugina, E. I., & Quigley, J. P. (2006). Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews, 25, 9-34.
6. Fingleton, B. (2006). Matrix metalloproteinases: Roles in cancer and metastasis. Frontiers in Bioscience, 11, 479-491.
7. Martin, M. D., & Matrisian, L. M. (2007). The other side of MMPs: Protective roles in tumor progression. Cancer and Metastasis Reviews, 26, 717-724.
8. Noel, A., Jost, M., & Maquoi, E. (2008). Matrix metalloproteinases at cancer tumor-host interface. Seminars in Cell & Developmental Biology, 19, 52-60.
9. Jodele, S., Blavier, L., Yoonm, J. M., & DeClerck, Y. A. (2006). Modifying the soil to affect the seed: Role of stromal-derived matrix metalloproteinases in cancer progression. Cancer and Metastasis Reviews, 25, 35-43.
10. Zucker, S., Pei, D., Cao, J., & Lopez-Otin, C. (2003). Membrane type-matrix metalloproteinases (MT-MMP). Current Topics in Developmental Biology, 54, 1-74.
11. Holmbeck, K., Bianco, P., Yamada, S., & Birkedal-Hansen, H. (2004). MT1-MMP: A tethered collagenase. Journal of Cellular Physiology, 200, 11-19.
12. Hotary, K., Li, X. Y., Allen, E., Stevens, S. L., & Weiss, S. J. (2006). A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes & Development, 20, 2673-2686.
13. Barbolina, M. V., & Stack, M. S. (2008). Membrane type 1-matrix metalloproteinase: Substrate diversity in pericellular proteolysis. Seminars in Cell & Developmental Biology, 19, 24-33.
14. Itoh, Y., & Seiki, M. (2006). MT1-MMP: A potent modifier of pericellular microenvironment. Journal of Cellular Physiology, 206, 1-8.
15. Osenkowski, P., Toth, M., & Fridman, R. (2004). Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). Journal of Cellular Physiology, 200, 2-10.
16. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., et al. (1994). A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature, 370, 61-65.
17. Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A., & Goldberg, G. I. (1995). Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. Journal of Biological Chemistry, 270, 5331-5338.
18. Arroyo, A. G., Genis, L., Gonzalo, P., Matias-Roman, S., Pollan, A., & Galvez, B. G. (2007). Matrix metalloproteinases: New routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease. Current Pharmaceutical Design, 13, 1787-1802.
19. Tanaka, M., Sato, H., Takino, T., Iwata, K., Inoue, M., & Seiki, M. (1997). Isolation of a mouse MT2-MMP gene from a lung cDNA library and identification of its product. FEBS Letters, 402, 219-222.
20. Takino, T., Sato, H., Shinagawa, A., & Seiki, M. (1995). Identification of the second membrane-type matrix metalloproteinase (MT- MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. Journal of Biological Chemistry, 270, 23013-23020.
21. Pei, D. (1999). Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. Journal of Biological Chemistry, 274, 8925-8932.
22. Llano, E., Pendas, A. M., Freije, J. P., Nakano, A., Knauper, V., Murphy, G., et al. (1999). Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Research, 59, 2570-2576.
23. Kajita, M., Kinoh, H., Ito, N., Takamura, A., Itoh, Y., Okada, A., et al. (1999). Human membrane type-4 matrix metalloproteinase (MT4-MMP) is encoded by a novel major transcript: Isolation of complementary DNA clones for human and mouse mt4-mmp transcripts. FEBS Letters, 457, 353-356.
24. Puente, X. S., Pendas, A. M., Llano, E., Velasco, G., & Lopez-Otin, C. (1996). Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Research, 56, 944-949.
25. Pei, D. (1999). Leukolysin/MMP25/MT6-MMP: A novel matrix metalloproteinase specifically expressed in the leukocyte lineage. Cell Research, 9, 291-303.
26. Velasco, G., Cal, S., Merlos-Suarez, A., Ferrando, A. A., Alvarez, S., Nakano, A., et al. (2000). Human MT6-matrix metalloproteinase: Identification, progelatinase A activation, and expression in brain tumors. Cancer Research, 60, 877-882.
27. Overall, C. M. (2001). Matrix metalloproteinase substrate binding domains, modules and exosites. Overview and experimental strategies. Methods in Molecular Biology, 151, 79-120.
28. Udenfriend, S., & Kodukula, K. (1995). How glycosylphosphatidylinositol-anchored membrane proteins are made. Annual Review in Biochemistry, 64, 563-591.
29. Itoh, Y., Kajita, M., Kinoh, H., Mori, H., Okada, A., & Seiki, M. (1999). Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase. Journal of Biological Chemistry, 274, 34260-34266.
30. Kang, T., Yi, J., Guo, A., Wang, X., Overall, C. M., Jiang, W., et al. (2001). Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils. Journal of Biological Chemistry, 276, 21960-21968.
31. Kojima, S., Itoh, Y., Matsumoto, S., Masuho, Y., & Seiki, M. (2000). Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP. FEBS Letters, 480, 142-146.
32. Sun, Q., Weber, C. R., Sohail, A., Bernardo, M. M., Toth, M., Zhao, H., et al. (2007). MMP25 (MT6-MMP) is highly expressed in human colon cancer, promotes tumor growth, and exhibits unique biochemical properties. Journal of Biological Chemistry, 282, 21998-22010.
33. Itoh, Y., Takamura, A., Ito, N., Maru, Y., Sato, H., Suenaga, N., et al. (2001). Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO Journal, 20, 4782-4793.
34. Lehti, K., Lohi, J., Juntunen, M. M., Pei, D., & Keski-Oja, J. (2002). Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase. Journal of Biological Chemistry, 277, 8440-8448.
35. Galvez, B. G., Genis, L., Matias-Roman, S., Oblander, S. A., Tryggvason, K., Apte, S. S., & Arroyo, A. G. (2005). Membrane type 1-matrix metalloproteinase is regulated by chemokines monocyte-chemoattractant protein-1/ccl2 and interleukin-8/CXCL8 in endothelial cells during angiogenesis. Journal of Biological Chemistry, 280, 1292-1298.
36. Rozanov, D. V., Deryugina, E. I., Ratnikov, B. I., Monosov, E. Z., Marchenko, G. N., & Quigley, J. P. (2001). Strongin AY: Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP). The role of the cytoplasmic tail Cys(574), the active site Glu(240), and furin cleavage motifs in oligomerization, processing, and self-proteolysis of MT1-MMP expressed in breast carcinoma cells. Journal of Biological Chemistry, 276, 25705-25714.
37. Paladino, S., Sarnataro, D., Pillich, R., Tivodar, S., Nitsch, L., & Zurzolo, C. (2004). Protein oligomerization modulates raft partitioning and apical sorting of GPI-anchored proteins. Journal of Cell Biology, 167, 699-709.
38. Paladino, S., Sarnataro, D., Tivodar, S., & Zurzolo, C. (2007). Oligomerization is a specific requirement for apical sorting of glycosyl-phosphatidylinositol-anchored proteins but not for non-raft-associated apical proteins. Traffic, 8, 251-258.
39. Sharom, F. J., & Lehto, M. T. (2002). Glycosylphosphatidylinositol- anchored proteins: Structure, function, and cleavage by phosphatidylinositol- specific phospholipase C. Biochemistry and Cell Biology, 80, 535-549.
40. Eisenhaber, B., Bork, P., & Eisenhaber, F. (1998). Sequence properties of GPI-anchored proteins near the omega-site: Constraints for the polypeptide binding site of the putative transamidase. Protein Engineering, 11, 1155-1161.
41. Eisenhaber, B., Bork, P., & Eisenhaber, F. (1999). Prediction of potential GPI-modification sites in proprotein sequences. Journal of Molecular Biology, 292, 741-758.
42. Eisenhaber, B., Bork, P., Yuan, Y., Loffler, G., & Eisenhaber, F. (2000). Automated annotation of GPI anchor sites: Case study C. elegans. Trends in Biochemical Sciences, 25, 340-341.
43. Ferguson, M. A., & Williams, A. F. (1988). Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures. Annual Review of Biochemistry, 57, 285-320.
44. Chen, R., Walter, E. I., Parker, G., Lapurga, J. P., Millan, J. L., Ikehara, Y., et al. (1998). Mammalian glycophosphatidylinositol anchor transfer to proteins and posttransfer deacylation. Proceedings of the National Academy of Sciences of the United States of America, 95, 9512-9517.
45. Maeda, Y., Tashima, Y., Houjou, T., Fujita, M., Yoko-o, T., Jigami, Y., et al. (2007). Fatty acid remodeling of GPI-anchored proteins is required for their raft association. Molecular Biology of the Cell, 18, 1497-1506.
46. Nebl, T., Pestonjamasp, K. N., Leszyk, J. D., Crowley, J. L., Oh, S. W., & Luna, E. J. (2002). Proteomic analysis of a detergent-resistant membrane skeleton from neutrophil plasma membranes. Journal of Biological Chemistry, 277, 43399-43409.
47. Stijlemans, B., Baral, T. N., Guilliams, M., Brys, L., Korf, J., Drennan, M., et al. (2007). A glycosylphosphatidylinositol-based treatment alleviates trypanosomiasis-associated immunopathology. Journal of Immunology, 179, 4003-4014.
48. Rollason, R., Korolchuk, V., Hamilton, C., Schu, P., & Banting, G. (2007). Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. Journal of Cell Science, 120, 3850-3858.
49. Paladino, S., Pocard, T., Catino, M. A., & Zurzolo, C. (2006). GPI-anchored proteins are directly targeted to the apical surface in fully polarized MDCK cells. Journal of Cell Biology, 172, 1023-1034.
50. Butler, G. S., & Overall, C. M. (2007). Proteomic validation of protease drug targets: Pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry. Current Pharmaceutical Design, 13, 263-270.
51. Kumari, S., & Mayor, S. (2008). ARF1 is directly involved in dynamin-independent endocytosis. Nature Cell Biology, 10, 30-41.
52. Jiang, A., Lehti, K., Wang, X., Weiss, S. J., Keski-Oja, J., & Pei, D. (2001). Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 98, 13693-13698.
53. Baker, A. H., Edwards, D. R., & Murphy, G. (2002). Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. Journal of Cell Science, 115, 3719-3727.
54. Brew, K., Dinakarpandian, D., & Nagase, H. (2000). Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochimica et Biophysica Acta, 1477, 267-283.
55. Chirco, R., Liu, X. W., Jung, K. K., & Kim, H. R. (2006). Novel functions of TIMPs in cell signaling. Cancer and Metastasis Reviews, 25, 99-113.
56. Maskos, K., & Bode, W. (2003). Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Molecular Biotechnology, 25, 241-266.
57. Lambert, E., Dasse, E., Haye, B., & Petitfrere, E. (2004). TIMPs as multifacial proteins. Critical Reviews in Oncology/Hematology, 49, 187-198.
58. Lee, M. H., Rapti, M., Knauper, V., & Murphy, G. (2004). Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. Journal of Biological Chemistry, 279, 17562-17569.
59. English, W. R., Puente, X. S., Freije, J. M., Knauper, V., Amour, A., Merryweather, A., et al. (2000). Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. Journal of Biological Chemistry, 275, 14046-14055.
60. Kolkenbrock, H., Essers, L., Ulbrich, N., & Will, H. (1999). Biochemical characterization of the catalytic domain of membrane-type 4 matrix metalloproteinase. Biological Chemistry, 380, 1103-1108.
61. Wang, Y., Johnson, A. R., Ye, Q. Z., & Dyer, R. D. (1999). Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain. Journal of Biological Chemistry, 274, 33043-33049.
62. English, W. R., Velasco, G., Stracke, J. O., Knauper, V., & Murphy, G. (2001). Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25). FEBS Letters, 491, 137-142.
63. Matsuda, A., Itoh, Y., Koshikawa, N., Akizawa, T., Yana, I., & Seiki, M. (2003). Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils. Journal of Biological Chemistry, 278, 36350-36357.
64. Shannan, B., Seifert, M., Leskov, K., Willis, J., Boothman, D., Tilgen, W., et al. (2006). Challenge and promise: Roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differentiation, 13, 12-19.
65. Rooney, I. A., Heuser, J. E., & Atkinson, J. P. (1996). GPI-anchored complement regulatory proteins in seminal plasma. An analysis of their physical condition and the mechanisms of their binding to exogenous cells. Journal of Clinical Investigation, 97, 1675-1686.
66. Robertson, C., Booth, S. A., Beniac, D. R., Coulthart, M. B., Booth, T. F., & McNicol, A. (2006). Cellular prion protein is released on exosomes from activated platelets. Blood, 107, 3907-3911.
67. Suzuki, K., & Okumura, Y. (2000). GPI-linked proteins do not transfer spontaneously from erythrocytes to liposomes. New aspects of reorganization of the cell membrane. Biochemistry, 39, 9477-9485.
68. Chabottaux, V., Sounni, N. E., Pennington, C. J., English, W. R., van den Brule, F., Blacher, S., et al. (2006). Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Research, 66, 5165-5172.
69. Lauc, G., & Heffer-Lauc, M. (2006). Shedding and uptake of gangliosides and glycosylphosphatidylinositol-anchored proteins. Biochimica et Biophysica Acta, 1760, 584-602.
70. Nie, J., & Pei, D. (2004). Rapid inactivation of alpha-1-proteinase inhibitor by neutrophil specific leukolysin/membrane-type matrix metalloproteinase 6. Experimental Cell Research, 296, 145-150.
71. Nie, J., & Pei, D. (2003). Direct activation of pro-matrix metalloproteinase-2 by leukolysin/membrane-type 6 matrix metalloproteinase/ matrix metalloproteinase 25 at the asn(109)-Tyr bond. Cancer Research, 63, 6758-6762.
72. Hotary, K. B., Yana, I., Sabeh, F., Li, X. Y., Holmbeck, K., Birkedal-Hansen, H., et al. (2002). Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. Journal of Experimental Medicine, 195, 295-308.
73. Grant, G. M., Giambernardi, T. A., Grant, A. M., & Klebe, R. J. (1999). Overview of expression of matrix metalloproteinases (MMP-17, MMP-18, and MMP-20) in cultured human cells. Matrix Biology, 18, 145-148.
74. Rikimaru, A., Komori, K., Sakamoto, T., Ichise, H., Yoshida, N., Yana, I., et al. (2007). Establishment of an MT4-MMP-deficient mouse strain representing an efficient tracking system for MT4-MMP/MMP-17 expression in vivo using beta-galactosidase. Genes Cells, 12, 1091-1100.
75. Rozanov, D. V., Hahn-Dantona, E., Strickland, D. K., & Strongin, A. Y. (2004). The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. Journal of Biological Chemistry, 279, 4260-4268.
76. Andolfo, A., English, W. R., Resnati, M., Murphy, G., Blasi, F., & Sidenius, N. (2002). Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thrombosis and Haemostasis, 88, 298-306.
77. Dumic, J., Dabelic, S., & Flogel, M. (2006). Galectin-3: An open-ended story. Biochimica et Biophysica Acta, 1760, 616-635.
78. McClung, H. M., Thomas, S. L., Osenkowski, P., Toth, M., Menon, P., Raz, A., et al. (2007). SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neuroscience Letters, 419, 172-177.
79. Ochieng, J., Fridman, R., Nangia-Makker, P., Kleiner, D. E., Liotta, L. A., Stetler-Stevenson, W. G., et al. (1994). Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry, 33, 14109-14114.
80. Toth, M., Osenkowski, P., Hesek, D., Brown, S., Meroueh, S., Sakr, W., et al. (2005). Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase. Biochemistry Journal, 387, 497-506.
81. Nagase, H. (1997). Activation mechanisms of matrix metalloproteinases. Biological Chemistry, 378, 151-160.
82. Giannelli, G., & Antonaci, S. (2002). Gelatinases and their inhibitors in tumor metastasis: From biological research to medical applications. Histology and Histopathology, 17, 339-345.
83. Bjorklund, M., & Koivunen, E. (2005). Gelatinase-mediated migration and invasion of cancer cells. Biochimica et Biophysica Acta, 1755, 37-69.
84. Hotary, K. B., Allen, E. D., Brooks, P. C., Datta, N. S., Long, M. W., & Weiss, S. J. (2003). Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell, 114, 33-45.
85. Stetler-Stevenson, W. G., & Yu, A. E. (2001). Proteases in invasion: Matrix metalloproteinases. Seminars in Cancer Biology, 11, 143-152.
86. Wolf, K., Wu, Y. I., Liu, Y., Geiger, J., Tam, E., Overall, C., et al. (2007). Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nature Cell Biology, 9, 893-904.
87. Hernandez-Barrantes, S., Bernardo, M., Toth, M., & Fridman, R. (2002). Regulation of membrane type-matrix metalloproteinases. Seminars in Cancer Biology, 12, 131-138.
88. Zhao, H., Bernardo, M. M., Osenkowski, P., Sohail, A., Pei, D., Nagase, H., et al. (2004). Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. Journal of Biological Chemistry, 279, 8592-8601.
89. Morrison, C. J., Butler, G. S., Bigg, H. F., Roberts, C. R., Soloway, P. D., & Overall, C. M. (2001). Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2-independent pathway. Journal of Biological Chemistry, 276, 47402-47410.
90. Will, H., Atkinson, S. J., Butler, G. S., Smith, B., & Murphy, G. (1996). The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. Journal of Biological Chemistry, 271, 17119-17123.
91. Miyamori, H., Takino, T., Kobayashi, Y., Tokai, H., Itoh, Y., Seiki, M., et al. (2001). Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. Journal of Biological Chemistry, 276, 28204-28211.
92. Tortorella, M. D., Burn, T. C., Pratta, M. A., Abbaszade, I., Hollis, J. M., Liu, R., et al. (1999). Purification and cloning of aggrecanase-1: A member of the ADAMTS family of proteins. Science, 284, 1664-1666.
93. Gao, G., Plaas, A., Thompson, V. P., Jin, S., Zuo, F., & Sandy, J. D. (2004). ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. Journal of Biological Chemistry, 279, 10042-10051.
94. Patwari, P., Gao, G., Lee, J. H., Grodzinsky, A. J., & Sandy, J. D. (2005). Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage. Osteoarthritis Cartilage, 13, 269-277.
95. Gauthier, M. C., Racine, C., Ferland, C., Flamand, N., Chakir, J., & Tremblay, G. M. (2003). Expression of membrane type-4 matrix metalloproteinase (metalloproteinase-17) by human eosinophils. International Journal of Biochemistry and Cell Biology, 35, 1667-1673.
96. Szabova, L., Yamada, S. S., Birkedal-Hansen, H., & Holmbeck, K. (2005). Expression pattern of four membrane-type matrix metalloproteinases in the normal and diseased mouse mammary gland. Journal of Cellular Physiology, 205, 123-132.
97. Nuttall, R. K., Pennington, C. J., Taplin, J., Wheal, A., Yong, V. W., Forsyth, P. A., et al. (2003). Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Molecular Cancer Research, 1, 333-345.
98. Wallard, M. J., Pennington, C. J., Veerakumarasivamm, A., Burtt, G., Mills, I. G., Warren, A., et al. (2006). Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. British Journal of Cancer, 94, 569-577.
99. Riddick, A. C., Shukla, C. J., Pennington, C. J., Bass, R., Nuttall, R. K., Hogan, A., et al. (2005). Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. British Journal of Cancer, 92, 2171-2180.
100. Noda, M., Oh, J., Takahashi, R., Kondo, S., Kitayama, H., & Takahashi, C. (2003). RECK: A novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer and Metastasis Reviews, 22, 167-175.
101. Tortorella, M. D., Arner, E. C., Hills, R., Easton, A., Korte-Sarfaty, J., Fok, K., et al. (2004). Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. Journal of Biological Chemistry, 279, 17554-17561.
102. Plaisier, M., Kapiteijn, K., Koolwijk, P., Fijten, C., Hanemaaijer, R., Grimbergen, J. M., et al. (2004). Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: Role of MT3-MMP. Journal of Clinical Endocrinology and Metabolism, 89, 5828-5836.